Interest rates. Real estate. Financial stocks. High-yielding dividend-payers. Those are some of the ...
Biotech: Room to Run
04/21/2015 9:00 am EST
Biotechnology has been one of the best performing industries in the stock market over the past several years, yet we think the industry's drivers, including a robust pipeline, remain intact and have a positive fundamental outlook, asserts Todd Rosenbluth, S&P Capital IQ Director of ETF Research in S&P's Marketscope.
Investors have increasingly utilized ETFs in a tactical manner to gain exposure to industries, while benefitting from the ability to make intra-day trades and benefit from their low-cost, passive nature.
iShares Nasdaq Biotechnology (IBB), First Trust NYSE Arca Biotechnology (FBT), and SPDR S&P Biotech (XBI)—the three largest, most direct ways to gain exposure to the biotech industry—experienced combined net inflows of more than $1.6 billion in 2014.
However, in the first two months, the trio had already added a collective $1.2 billion of inflows. While IBB and FBT primarily provide exposure to larger-cap biotechs, IBB is more concentrated. Top-10 assets comprised 56% of assets compared to 34% for FBT.
S&P Capital IQ views all four of the stocks as undervalued on both a qualitative and quantitative basis, and not surprisingly, the ETF ranks favorably from both a STARS and Fair Value perspective.
Meanwhile, FBT holds just 30 stocks compared to 153 for IBB, but is equally weighted and rebalanced four times a year. Both of these ETFs also provide exposure to pharmaceutical and life sciences stocks.
Meanwhile, SPDR S&P Biotech holds just biotechnology stocks yet has more exposure to smaller-caps. Indeed, XBI's weighted average market cap was $8 billion, compared to IBB's $44 billion and FBT's $24 billion.
In 2014, FBT climbed 48%, outperforming the otherwise impressive 45% and 34% for XBI and IBB, respectively. Year to date through March 25, SPDR S&P Biotech was the stronger performer of the trio. However, past performance is not necessarily indicative of future results.
We think SPDR S&P Biotech’s inclusion of smaller-caps contributed to its higher standard deviation relative to First Trust NYSE Arca Biotechnology and iShares Nasdaq Biotechnology. However, with a 0.35% expense ratio, SPDR S&P Biotech is the cheapest of the three.
More from MoneyShow.com:
Related Articles on ETFs
Trade idea: As long as FXI trades below $49.85, then new short trade ideas can be initiated between ...
The probability of an equity market correction over the next few months is slim to none, so there co...
Trade idea: As long as LQD trades below $122.60, then new short trade ideas can be initiated between...